NHS
Generic version of Pfizer’s Lyrica launched
March 25, 2015Sales and Marketing CCG, Lyrica, NHS, Pfizer, consilient health, pregabalin, rewisca
A UK pharma firm has launched a cut-price version of Pfizer’s Lyrica along with a bespoke supply chain to ensure …
Budget 2015: £1.25 billion boost for mental health services
March 20, 2015Sales and Marketing Budget, Cameron, Miliband, NHS, Osborne, UK
Senior NHS figures have hit out at Chancellor George Osborne’s failure to lay out any specific plans concerning the future …
Type 1 diabetes market value to double by 2023
March 19, 2015Research and Development, Sales and Marketing GlobalData, NHS, NICE, Sanofi, diabetes, toujeo, type 1
The treatment market for type 1 diabetes is set to double to around $13.6 billion by 2023 according to analysts …
NHS is struggling to improve cancer care
March 16, 2015Sales and Marketing CRUK, Cancer, Department of Health, NHS, NHS England, oncology
The Department of Health and NHS England are struggling with the demand required to improve its cancer services according to …
Drug development contracts: can lessons be learned from healthcare delivery?
March 16, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CCG, CRO, Les Rose, NHS, drug development, trials
There is a very good question to ask at the beginning of every project: “What does success look like?” If …
Pharma pays £310 million underwriting UK meds bill
March 13, 2015Sales and Marketing ABPI, NHS, PPRS, body, department, health pricing, pharma
Pharma has made a fourth quarter payment of £81 million to underwrite the 2014 UK medicines bill under the Pharmaceutical …
Takeda gets NICE nod for bowel treatment
March 13, 2015Sales and Marketing NHS, NICE, Takeda, enyyvio, vedolizumab
Takeda’s Entyvio becomes the first NICE approved gut-selective treatment for UK patients with ulcerative colitis (UC) – a long-term condition …
NHS backtracks on Cancer Drugs Fund de-listings
March 12, 2015Sales and Marketing Afinitor, CDF, Cancer Drugs Fund, England, Halaven, NHS, Novartis, everolimus
NHS England is expected to perform a U-turn on several decisions to remove treatments from the cancer drugs fund when …
Government pledges ‘new era’ for NHS
March 11, 2015Research and Development, Sales and Marketing NHS, Simon Stevens, five year, reform, reorganisation, vanguard
The government is investing £200 million to back healthcare professionals to implement their own ideas for improving patient care. The …
New details of Innovative Medicines review disclosed
March 11, 2015Research and Development, Sales and Marketing ABPI, NHS, NICE, PPRS, UK, george freeman, innovative medicines
The government has announced details of a sweeping review into how medicines are accessed in the UK. The Innovative Medicines …
Oncologists say CDF cuts will compromise treatment
March 10, 2015Sales and Marketing CDF, Jevtana, NHS, NICE, Sanofi, cabazitaxel, doctors.net, m3
Oncologists believe cutting drugs from the Cancer Drugs Fund won’t save the NHS money and will worsen patient outcomes according …
Government lays out rare diseases plan
March 5, 2015Sales and Marketing Department of Health, NHS, UK, government, howe, rare diseases
The UK government has set out new plans to improve the lives of patients with rare diseases by 2020. The …
Scottish reforms proven to work says SMC
March 4, 2015Sales and Marketing NHS, NICE, Onglyza, PACE, SMC, Scotland, anne lee, scottish
The chief pharma advisor for the Scottish Medicines Consortium Anne Lee says changes to its processes have contributed to improved …
Gilead frustrated despite final NICE Sovaldi nod
February 25, 2015Sales and Marketing Gilead, NHS, NICE, hep C, hepatitis, sofosbuvir, sovaldi
NICE has published final guidance confirming its approval of Gilead’s controversial blockbuster hepatitis C treatment Sovaldi – but Gilead and …
Doctors appeal to prescribe Avastin off-label
February 25, 2015Sales and Marketing Lucentis, NHS, NICE, Novartis, Roche, bevacizumab, wet AMD
NHS Clinical Commissioners have called for the removal of barriers preventing CCGs from prescribing Roche’s Avastin to treat wet age-related …
Latest content
Trio become latest Symbiosis commercial additions
UK immunoglobulin supply faces growing pressure, report warns
How will biomarker-led diagnostics reshape respiratory medicine?
